Last $105.59 USD
Change Today -0.34 / -0.32%
Volume 9.0M
GILD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Xetra
As of 12:32 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GILD) Snapshot

Open
$107.75
Previous Close
$105.93
Day High
$107.89
Day Low
$105.51
52 Week High
09/3/14 - $110.64
52 Week Low
10/9/13 - $58.81
Market Cap
159.6B
Average Volume 10 Days
16.8M
EPS TTM
$4.52
Shares Outstanding
1.5B
EX-Date
--
P/E TM
23.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for GILEAD SCIENCES INC (GILD)

gilead sciences inc (GILD) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

6,100 Employees
Last Reported Date: 02/25/14
Founded in 1987

gilead sciences inc (GILD) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $746.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $884.2K
Senior Advisor
Total Annual Compensation: $810.4K
Compensation as of Fiscal Year 2013.

gilead sciences inc (GILD) Key Developments

Gilead Sciences Inc. Announces Data from Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer

Gilead Sciences Inc. announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab (200 mg or 700 mg) to gemcitabine did not significantly increase progression-free survival (PFS) compared to placebo plus gemcitabine. In this randomized, double-blind, placebo-controlled Phase 2 trial, 236 patients with advanced pancreatic cancer received intravenous gemcitabine plus either intravenous simtuzumab (200 mg, n=76; 700 mg, n=79) or placebo (n=81) in cycles of 28 days. Median PFS for the simtuzumab 200 mg, simtuzumab 700 mg and placebo groups was 3.5 months, 3.7 months and 3.7 months, respectively. The difference in PFS between the simtuzumab and placebo arms was not statistically significant. Expected gemcitabine-related toxicities included anemia, thrombocytopenia, neutropenia and nausea. There was no difference in adverse events between patients taking simtuzumab versus placebo.

Hetero Enters License Agreement with Gilead Sciences Inc. to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis

Hetero Group announced that it has obtained licensing rights to manufacture and market sofosbuvir and combination drug ledipasvir/sofosbuvir upon approval from Gilead Sciences Inc., USA for 90 countries. Under the said agreement, Hetero is entitled to manufacture and market sofosbuvir and ledipasvir/sofosbuvir in the territories of India, Asia Pacific, Sub-Saharan Africa and other Least Developed Countries. This will expand access of affordable medicines to patients who are infected with chronic hepatitis C in various developing countries. This licensing association marks a significant milestone in ensuring the medicines are accessible globally and thereby addressing the significant public health care issue.

Strides Arcolab Limited Announces Licensing Agreement with Gilead Sciences Inc to Produce Generic Sofosbuvir and Investigational Single Tablet Regimen of Ledipasvir/Sofosbuvir for Treatment of Chronic Hepatitis C

Strides Arcolab Limited announced that Gilead Sciences Inc. has licensed Strides to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C, for distribution to 91 developing countries including India, Eqypt & Indonesia which are high burden countries. Under the licensing agreements, Strides receives a complete technology transfer of the Gilead manufacturing process for both API & finished product to enable scale up production as quickly as possible. Strides can also set its own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other business essential activities. The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $105.59 USD -0.34

GILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.21 USD -0.24
Amgen Inc $143.23 USD +1.21
AstraZeneca PLC 4,579 GBp +42.00
Bristol-Myers Squibb Co $51.55 USD +0.43
Eli Lilly & Co $66.42 USD -0.175
View Industry Companies
 

Industry Analysis

GILD

Industry Average

Valuation GILD Industry Range
Price/Earnings 24.0x
Price/Sales 9.3x
Price/Book 10.0x
Price/Cash Flow 21.5x
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.